Quality by design: optimization of letrozole solid lipid nanoparticle for breast cancer
By: Priyadarsini, Sowmya
.
Contributor(s): Lahoti, Swaroop Rameshwarji.
Publisher: Bangalore Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(4), Oct-Dec.Description: 1013-1024p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Aim: Hormone responsive breast cancer is the most prevalent cancer worldwide. Letrozole
is a third-generation aromatase inhibitor widely used for the treatment of advanced
breast cancer. The primary objective of the present work is to develop and optimize an
injectable solid lipid nanoparticle incorporating letrozole to circumvent the side-effects of
a marketed conventional formulation and thereby improve patient compliance. Materials
and Methods: Emulsification solvent evaporation and melt dispersion techniques were
used for formulating the said solid lipid nanoparticles. Quality by design concept was
used for the development and optimization of formulation and process variables. Results:
The optimum level selected is 60 mg lipid, 30 mg surfactant, and co-surfactant, 15000
psi HPH pressure, and 15 HPH passes. Conclusion: Glyceryl dibehenate was selected as
suitable lipid based on solubility and partition coefficient. With an increase in lipid content
there is increase in particle size and PDI and decrease in entrapment efficiency. Higher
surfactant and co-surfactant concentrations result in lower particle size, PDI, higher zeta
potential, and lower entrapment efficiency. An increase in HPH pressure reduced particle
size and PDI up to a certain level, however, the increase in HPH pressure from 15000
to 20000 psi increased particle size. An increase in the number of HPH passes reduces
particle size and PDI. The drug release mechanism for LTR-SLN was found to follow the
first order and higuichi model.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2023-0097 |
Aim: Hormone responsive breast cancer is the most prevalent cancer worldwide. Letrozole
is a third-generation aromatase inhibitor widely used for the treatment of advanced
breast cancer. The primary objective of the present work is to develop and optimize an
injectable solid lipid nanoparticle incorporating letrozole to circumvent the side-effects of
a marketed conventional formulation and thereby improve patient compliance. Materials
and Methods: Emulsification solvent evaporation and melt dispersion techniques were
used for formulating the said solid lipid nanoparticles. Quality by design concept was
used for the development and optimization of formulation and process variables. Results:
The optimum level selected is 60 mg lipid, 30 mg surfactant, and co-surfactant, 15000
psi HPH pressure, and 15 HPH passes. Conclusion: Glyceryl dibehenate was selected as
suitable lipid based on solubility and partition coefficient. With an increase in lipid content
there is increase in particle size and PDI and decrease in entrapment efficiency. Higher
surfactant and co-surfactant concentrations result in lower particle size, PDI, higher zeta
potential, and lower entrapment efficiency. An increase in HPH pressure reduced particle
size and PDI up to a certain level, however, the increase in HPH pressure from 15000
to 20000 psi increased particle size. An increase in the number of HPH passes reduces
particle size and PDI. The drug release mechanism for LTR-SLN was found to follow the
first order and higuichi model.
Click on an image to view it in the image viewer
There are no comments for this item.